What's new? Log in Free sign up

PepGen (PEPG)

Company Profile

Company profile

Ticker

PEPG

Exchange

Website

CEO

Dr. Michelle L. Mellion M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

Incumaker, Inc., uBid Holdings, Inc./New

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

PEPG stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$9.00

Low target

$6.00

High target

$12.00

B of A Securities

Latest filings (excl ownership)

View all

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51

Quarterly report

7 Nov 24

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

PepGen Announces Positive Data from Low-Dose Cohort of

Notice of effectiveness

Shelf registration

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

VIKING GLOBAL INVESTORS LP

JANUS HENDERSON GROUP PLC

Qatar Investment Authority

Michelle L Mellion

Michelle L Mellion

Michelle L Mellion

Michelle L Mellion

Michelle L Mellion

Financial summary

Financial statements Chart PEPG financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	43.84 mm	43.84 mm	43.84 mm	43.84 mm	43.84 mm	43.84 mm
Cash burn (monthly)	30.51 mm	8.72 mm	7.72 mm	7.38 mm	(no burn)	4.84 mm
Cash used (since last report)	85.40 mm	24.42 mm	21.62 mm	20.66 mm	n/a	13.54 mm
Cash remaining	-41.56 mm	19.41 mm	22.21 mm	23.18 mm	n/a	30.30 mm
Runway (months of cash)	-1.4	2.2	2.9	3.1	n/a	6.3

Beta Read what these cash burn values mean

Financial data from PepGen earnings reports.

Institutional ownership, Q2 2024

PEPG institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	63	49	+28.6%
Opened positions	22	16	+37.5%
Closed positions	8	9	-11.1%
Increased positions	22	13	+69.2%
Reduced positions	12	12	–

13F shares	Current	Prev Q	Change
Total value	401.15 bn	259.11 bn	+54.8%
Total shares	27.35 mm	19.84 mm	+37.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Ra Capital Management	10.69 mm	$170.61 bn	0.0%
Suvretta Capital Management	1.52 mm	$24.27 bn	NEW
Frazier Life Sciences Management	1.50 mm	$23.98 bn	0.0%
Viking Global Investors	1.48 mm	$23.66 bn	NEW
Perceptive Advisors	1.41 mm	$22.51 bn	NEW
Adage Capital Partners GP, L.L.C.	1.33 mm	$21.19 bn	-0.5%
Qatar Investment Authority	1.24 mm	$0.00	0.0%
BLK BlackRock	1.04 mm	$16.58 bn	+32.9%
Flynn James E	953.63 k	$0.00	0.0%
Vanguard	903.39 k	$14.42 bn	+6.2%

Largest transactions	Shares	Bought/sold	Change
Suvretta Capital Management	1.52 mm	+1.52 mm	NEW
Viking Global Investors	1.48 mm	+1.48 mm	NEW
Perceptive Advisors	1.41 mm	+1.41 mm	NEW
Laurion Capital Management	841.43 k	+841.43 k	NEW
JHG Janus Henderson	541.88 k	+541.88 k	NEW
Polar Capital	531.10 k	+531.10 k	NEW
Octagon Capital Advisors	376.12 k	+376.12 k	NEW
BLK BlackRock	1.04 mm	+257.32 k	+32.9%
IVZ Invesco	231.06 k	+231.06 k	NEW
Woodline Partners	174.04 k	+174.04 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PEPG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Aug 24	Paul Streck	Stock Option Common Stock	Grant	Acquire A	No	No	9.83	40,000	393.20 k	242,816
19 Aug 24	Paul Streck	Stock Option Common Stock	Grant	Acquire A	No	No	9.83	202,816	1.99 mm	202,816
25 Jul 24	Michelle L Mellion	Common Stock	Sell	Dispose S	No	Yes	18.0612	7,571	136.74 k	0
25 Jul 24	Michelle L Mellion	Common Stock	Option exercise	Acquire M	No	Yes	10.21	7,571	77.30 k	7,571
25 Jul 24	Michelle L Mellion	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	10.21	7,571	77.30 k	50,000
24 Jul 24	Michelle L Mellion	Common Stock	Sell	Dispose S	No	Yes	18.0051	201	3.62 k	0
24 Jul 24	Michelle L Mellion	Common Stock	Option exercise	Acquire M	No	Yes	10.21	201	2.05 k	201
24 Jul 24	Michelle L Mellion	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	10.21	201	2.05 k	57,571
18 Jul 24	Michelle L Mellion	Common Stock	Sell	Dispose S	No	Yes	18.2023	12,625	229.80 k	0
18 Jul 24	Michelle L Mellion	Common Stock	Option exercise	Acquire M	No	Yes	10.21	12,625	128.90 k	12,625

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

PepGen Announces Clinical Hold In The U.S. On IND Application To Initiate CONNECT2-EDO51 Phase 2 Study Of PGN-EDO51 For Duchenne Muscular Dystrophy; Continues To Advance PGN-EDO51 In CONNECT1-EDO51, With The 10 mg/kg Cohort Now Fully Enrolled

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled-PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

B of A Securities Maintains Neutral on PepGen, Lowers Price Target to $6

Press releases

From Benzinga Pro

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

– FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 – – Study designs of CONNECT program optimized based on encouraging results from early cohort – – Strengthened

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.